Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS)
CNY 19.25
(-3.12%)
CNY 19.25
(-3.12%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.06 Billion CNY | 32.37% |
| 2022 | 2.31 Billion CNY | 31.3% |
| 2021 | 1.76 Billion CNY | 15.76% |
| 2020 | 1.52 Billion CNY | 39.99% |
| 2019 | 1.08 Billion CNY | -0.49% |
| 2018 | 1.09 Billion CNY | 35.28% |
| 2017 | 807.2 Million CNY | 50.61% |
| 2016 | 535.94 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 3.1 Billion CNY | -0.02% |
| 2024 Q2 | 3.1 Billion CNY | 2.66% |
| 2024 Q1 | 3.02 Billion CNY | -1.05% |
| 2023 Q3 | 2.65 Billion CNY | 4.18% |
| 2023 Q2 | 2.54 Billion CNY | 8.17% |
| 2023 FY | 3.06 Billion CNY | 32.37% |
| 2023 Q1 | 2.35 Billion CNY | 1.77% |
| 2023 Q4 | 3.06 Billion CNY | 15.42% |
| 2022 Q4 | 2.31 Billion CNY | 26.26% |
| 2022 Q3 | 1.83 Billion CNY | 1.88% |
| 2022 Q2 | 1.79 Billion CNY | 5.68% |
| 2022 Q1 | 1.7 Billion CNY | -3.41% |
| 2022 FY | 2.31 Billion CNY | 31.3% |
| 2021 Q1 | 1.52 Billion CNY | 0.25% |
| 2021 Q4 | 1.76 Billion CNY | 19.11% |
| 2021 FY | 1.76 Billion CNY | 15.76% |
| 2021 Q2 | 1.4 Billion CNY | -8.04% |
| 2021 Q3 | 1.47 Billion CNY | 5.42% |
| 2020 Q2 | 1.18 Billion CNY | 5.92% |
| 2020 Q4 | 1.52 Billion CNY | 9.57% |
| 2020 FY | 1.52 Billion CNY | 39.99% |
| 2020 Q3 | 1.38 Billion CNY | 17.41% |
| 2020 Q1 | 1.11 Billion CNY | 2.74% |
| 2019 Q2 | 1.12 Billion CNY | 0.0% |
| 2019 FY | 1.08 Billion CNY | -0.49% |
| 2019 Q1 | - CNY | 0.0% |
| 2019 Q4 | 1.08 Billion CNY | 0.0% |
| 2018 FY | 1.09 Billion CNY | 35.28% |
| 2017 FY | 807.2 Million CNY | 50.61% |
| 2016 FY | 535.94 Million CNY | 0.0% |